Ensysce Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ENSC$0.33-8.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Unaudited)
| September 30, 2024 · December 31, 2023 | ||||
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $4,153,592 | $1,123,604 | ||
| Unbilled receivable | 1,782,805 | 97,561 | ||
| Prepaid expenses and other current assets | 3,154,110 | 1,067,703 | ||
| Total current assets | 9,090,507 | 2,288,868 | ||
| Other assets | 294,217 | 419,217 | ||
| Total assets | $9,384,724 | $2,708,085 | ||
| Liabilities and stockholders’ equity (deficit) | ||||
| Current liabilities: | ||||
| Accounts payable | $1,967,573 | $1,936,007 | ||
| Accrued expenses and other liabilities | 447,035 | 542,260 | ||
| Notes payable and accrued interest | 387,176 | 854,697 | ||
| Total current liabilities | 2,801,784 | 3,332,964 | ||
| Long-term liabilities: | ||||
| Liability classified warrants | 3,213 | 26,388 | ||
| Total long-term liabilities | 3,213 | 26,388 | ||
| Total liabilities | $2,804,997 | $3,359,352 | ||
| Commitments and contingencies (Note 6) | - | - | ||
| Stockholders’ equity (deficit) | ||||
| Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2024 (unaudited) and December 31, 2023 | $ | - | $ | - |
| Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2024 (unaudited) and December 31, 2023; 13,870,591 and 3,146,157 shares issued at September 30, 2024 (unaudited) and December 31, 2023, respectively; 13,870,510 and 3,146,076 shares outstanding at September 30, 2024 (unaudited) and December 31, 2023, respectively | 1,387 | 315 | ||
| Additional paid-in capital | 132,886,700 | 121,233,901 | ||
| Accumulated deficit | (125,979,877) | (121,557,074) | ||
| Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) | 6,908,210 | (322,858) | ||
| Noncontrolling interests in stockholders’ deficit | (328,483) | (328,409) | ||
| Total stockholders’ equity (deficit) | 6,579,727 | (651,267) | ||
| Total liabilities and stockholders’ equity (deficit) | $9,384,724 | $2,708,085 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.